感染性心内膜炎治疗新药——达托霉素  

New drug to treat patients with infective endocarditis,daptomycin

作　　者：刘浩[1] 许茜[1] 白楠[1] 王睿[1] 

机构地区：[1]中国人民解放军总医院药品保障中心,北京100853

出　　处：《中国临床药理学杂志》2010年第6期462-465,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：感染性心内膜炎是心脏心内膜微生物感染引起的疾病,患者死亡率达16%～25%。导致感染性心内膜炎的病原微生物很多,金黄色葡萄球菌是最常见的致病菌。具有杀菌活性的抗生素被认为是治疗感染性性心内膜炎患者的金标准。近年来,随着耐甲氧西林金黄色葡萄球菌对β内酰胺类抗生素耐受的出现及万古霉素的使用增加,导致了MRSA对其敏感度的下降,出现了耐万古霉素的金黄色葡萄球菌。于是出现了治疗感染性心内膜炎的新药——达托霉素。Infective endocarditis is a disease caused by endocardium＇s microbe infection, and its mortality rate could be as high as 16% -25%. There are many pathogenic microorganisms that could lead to infective endocarditis, of which Staphylococcus aureus is commonly seen. Antibiotics with bactericidal activity are known as the gold standard to treat infective endocarditis. Recently, methicillin -resistant Staphylococcus aureus （MRSA） begin to tolerate with β - lactam antibiotics, as a result, vancomycin is the first choice to manage serious MRSA infection. However, the increasing of vancomycin results in the decrease of MRSA＇s sensitivity, and vancomycin -resistant Staphylococcus aureus appeared. A new drug was found, daptomycin,to treat infective endocarditis.

关 键 词：达托霉素 感染性心内膜炎 金黄色葡萄球菌 

分 类 号：R542.42[医药卫生—心血管疾病] R978.12[医药卫生—内科学]